⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLMD News
Galmed Pharmaceuticals Ltd.
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
prnewswire.com
GLMD
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
prnewswire.com
GLMD
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
prnewswire.com
GLMD
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
prnewswire.com
GLMD
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
prnewswire.com
GLMD
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
prnewswire.com
GLMD
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
prnewswire.com
GLMD
Galmed Issues CEO Letter to Shareholders
prnewswire.com
GLMD
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
prnewswire.com
GLMD
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
prnewswire.com
GLMD